Lilly takes long view on Alzheimer’s drug hopeful as FDA starts expedited review

cafead

Administrator
Staff member
  • cafead   Aug 05, 2022 at 11:32: AM
via The Food and Drug Administration has agreed to an expedited review of Eli Lilly’s experimental Alzheimer’s disease medicine donanemab, the pharmaceutical company said Thursday.

article source